TCEAL7 has been identified to be frequently deregulated in tumors, and its decreased expression often correlates with malignant clinical process and poor prognosis in several kinds of cancers, such as ovarian cancer [4], gastric adenocarcinoma [6] and non-small cell lung cancer [7]. Here, TCEAL7 is linked to gastric adenocarcinoma.